Log in

Relevant bibliographies by topics / Auto lymphocyte therapy / Journal articles

To see the other types of publications on this topic, follow the link: Auto lymphocyte therapy.

Journal articles on the topic 'Auto lymphocyte therapy'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Auto lymphocyte therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sackstein, Robert, Jane L. Messina, and Gerald J. Elfenbein. "In vitro adherence of lymphocytes to dermal endothelium under shear stress: implications in pathobiology and steroid therapy of acute cutaneous GVHD." Blood 101, no. 2 (2003): 771–78. http://dx.doi.org/10.1182/blood-2002-05-1452.

Full text

Abstract:

The extravasation of leukocytes at sites of inflammation critically depends on initial shear-resistant adhesive interactions between leukocytes in blood flow and target tissue endothelium. Dermal lymphocytic infiltrates are a hallmark feature of acute cutaneous graft-versus-host disease (acGVHD) following allogeneic hematopoietic stem cell (allo-HSC) transplantation. These infiltrates occur commonly during periods of profound lymphopenia, suggesting that the dermal endothelial adhesive mechanism(s) promoting lymphocyte emigration in acGVHD are highly efficient. To examine this issue, we perfor

APA, Harvard, Vancouver, ISO, and other styles

2

Moturi, Krishna, Harsh Sharma, and Neda Hashemi-Sadraei. "Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management." International Journal of Molecular Sciences 25, no. 1 (2023): 414. http://dx.doi.org/10.3390/ijms25010414.

Full text

Abstract:

Immune checkpoint inhibitors (ICI) revolutionized cancer therapy by augmenting anti-tumor immunity via cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1/programmed death-ligand 1 (PD-1/PD-L1). However, this breakthrough is accompanied by immune-related adverse effects (irAEs), including renal complications. ICI-related nephritis involves complex mechanisms like auto-reactive T cells, auto-antibodies, reactivation of drug-specific T cells, and cytokine-driven inflammation culminating in AKI. ICI-AKI typically manifests weeks to months into treatment, often with other i

APA, Harvard, Vancouver, ISO, and other styles

3

Esina, E. "An Experience of Intravaginal Auto Lymphocyte Therapy in Treatment of Female Patients with Infertility: A Case Report." British Journal of Medicine and Medical Research 2, no. 2 (2012): 150–56. http://dx.doi.org/10.9734/bjmmr/2012/904.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rose, Ashley, Quinto J. Gesiotto, Leidy Isenalumhe, et al. "Lymphocyte Recovery Following Autologous Hematopoietic Stem Cell Transplant in Classical Hodgkin Lymphoma." Blood 138, Supplement 1 (2021): 2913. http://dx.doi.org/10.1182/blood-2021-150542.

Full text

Abstract:

Abstract Introduction: The standard of care for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous hematopoietic stem cell transplant (auto-HCT). Pre-apheresis absolute lymphocyte count (PA-ALC) is an independent prognostic factor for overall survival (OS) after transplant. We aimed to evaluate the effect of absolute lymphocyte count following auto-HCT and hypothesized that a higher post-transplant ALC at day +15 (PT-ALC) correlates with improved OS. Methods: A retrospective review was performed on patients with R/R cHL who underwent auto-HCT a

APA, Harvard, Vancouver, ISO, and other styles

5

Gul, Zartash, Stephan Anderson, Stacey Slone, et al. "Is Rituximab Needed With High Dose Chemotherapy and Autologous Stem Cell Transplant When Patients With Non-Hodgkin’s Lymphoma Have Been Exposed To It?" Blood 122, no. 21 (2013): 5552. http://dx.doi.org/10.1182/blood.v122.21.5552.5552.

Full text

Abstract:

Abstract Introduction The value of Rituximab with High dose chemotherapy and autologous stem cell transplant (auto-HCT) has been evaluated in some retrospective studies. It is noted that the addition Rituximab to auto-HCT results in significant improvement in overall (OS) and disease free survival (DFS). However, it is unclear that the addition of Rituximab with auto-HCT would result in significant benefit in patients who have received prior Rituximab based therapy. Methods We retrospectively evaluated twenty seven consecutive patients who had B cell non-Hodgkin's lymphoma (NHL) and underwent

APA, Harvard, Vancouver, ISO, and other styles

6

Moviglia, G. A., C. Gaeta, G. Varela, et al. "Tumor-associated stroma cell therapy in patients with pancreatic cancer potentiates therapeutic effect of tumor B-cell hybrid (TBH) auto-vaccines." Journal of Clinical Oncology 25, no. 18_suppl (2007): 4569. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4569.

Full text

Abstract:

4569 Background: Pancreatic Cancer (PC) tumor-associated stroma cells play an important role in PC’s immune surveillance escape. Secretion of Transforming Growth Factor β (TGFβ) and IL10 by PC tumor cells disturb the antigen presenting function of the stroma cells. It may explain the poor results of most immunotherapeutic approaches. Granger et al. reported a successful approach for treating small size pancreatic tumors, namely Mixed Lymphocyte Culture (MLC) cytoimplant. MLC cytoimplants, acting as a Th1 cytokine pump inside the tumor, are thought to revert the tumor-associated stroma cell dys

APA, Harvard, Vancouver, ISO, and other styles

7

Kil'dyushevskiy, A. V., V. A. Molochkov, T. A. Mitina, Ya G. Moysyuk, and A. V. Molochkov. "Extracorporeal photopheresis as a non-specific immune therapy of autoimmune diseases and skin T-cell lymphoma (a review of the literature and own studies)." Almanac of Clinical Medicine 47, no. 5 (2019): 419–34. http://dx.doi.org/10.18786/2072-0505-2019-47-061.

Full text

Abstract:

Aim: To present well-known and disputable mechanisms of the effects of extracorporeal photopheresis (ECP) in heterogeneous clinical conditions, as well as to demonstrate its advantages over conventional hormonal, immunosuppressive and cytostatic treatments, with a recommendation to widely implement it into practical management of autoimmune disease and cutaneous T-cell lymphomas (CTCLs).Key points: Despite convincing evidence of the ECP efficacy in the treatment of T-cell mediated disorders, a unifying concept of its mechanism has not been established so far. In this review, we attempted to de

APA, Harvard, Vancouver, ISO, and other styles

8

Stover, D. G., V. K. Reddy, Y. Shyr, B. N. Savani, and N. Reddy. "Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma." Bone Marrow Transplantation 47, no. 1 (2011): 82–87. http://dx.doi.org/10.1038/bmt.2011.29.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Milovanovic, Ivan, Nevena Popovac, Aleksandar Sretenovic, Nina Ristic, and Radmila Jankovic. "Autoimmune intestinal leiomyositis as a rare cause of chronic intestinal pseudo-obstruction in children: Case report with literature review." Srpski arhiv za celokupno lekarstvo, no. 00 (2025): 8. https://doi.org/10.2298/sarh241210008m.

Full text

Abstract:

Introduction. Chronic intestinal pseudo-obstruction represents a group of rare disorders characterized by impaired gastrointestinal motility in the absence of mechanical bowel obstruction. These disorders can be primary or secondary, with autoimmune intestinal leiomyositis falling into the latter category. This condition is observed in adolescence and adulthood but is very rarely seen in children, especially in infancy. Case outline. A nine-month-old male infant was hospitalized due to persistent vomiting, abdominal bloating, and distension. After diagnostic evaluations and failure of conserva

APA, Harvard, Vancouver, ISO, and other styles

10

Zimmerman, Daniel, Katalin Mikecz, Julia Kurko, Tibor Glant, Harold Steiner, and Roy Carambula. "LEAPS peptide vaccination alters T cell phenotype and suppresses joint inflammation in a murine model of rheumatoid arthitis (P5223)." Journal of Immunology 190, no. 1_Supplement (2013): 67.6. http://dx.doi.org/10.4049/jimmunol.190.supp.67.6.

Full text

Abstract:

Abstract Introduction. A major therapeutic goal in autoimmune inflammatory diseases such as rheumatoid arthritis (RA) is to suppress responses against (auto)antigens present in the target organs. Antigen-specific therapies such as the Ligand Epitope Antigen Presentation System (LEAPS) technology offer such a possibility. Materials and Methods. We evaluated LEAPS therapy in the cartilage proteoglycan (PG) induced arthritis (PGIA) model of RA. After the onset of PGIA, mice were divided in 3 groups, each with a similar mean arthritis index (AI). One group was vaccinated with adjuvant only, and th

APA, Harvard, Vancouver, ISO, and other styles

11

Luo, Chengjuan, Yanjing Tang, Changying Luo, et al. "One-Stop No-Edited Allogenic CAR-T Therapy Bridging HSCT to Treat Children with Relapse and Refractory Acute Lymphoblastic Leukemia: A Prospective Clinical Study from a Single Center." Blood 142, Supplement 1 (2023): 3615. http://dx.doi.org/10.1182/blood-2023-188448.

Full text

Abstract:

Object: Chimeric Antigen Receptor T-Cell (CAR-T) therapy has been developed to be the most effective treatment for relapse and refractory(R/R) B-cell acute lymphoblastic leukemia(B-ALL). However, in some patients prolonged chemotherapy and previous autologous-CAR-T(auto-CAR-T) therapy severely impaired lymphocyte function leading to inability in vitro expansion for effective CAR-T therapy. To address this challenge, we designed this clinical trail to use one-stop no-edited allogenic CAR-T（allo-CART）bridging to same donor conditioning free HSCT to treat children with R/R B-ALL. Methods: Myeloab

APA, Harvard, Vancouver, ISO, and other styles

12

Chen, Allen, Allan Hess, Sharon Gardner та ін. "Cyclosporine, Interferon-γ , and Interleukin-2 Immunotherapy Is Tolerable and Induces Autoreactivity in Patients with Recurrent/Refractory Hodgkin Disease Undergoing Autologous Stem Cell Transplantation with BEAM: A COG Study." Blood 106, № 11 (2005): 2087. http://dx.doi.org/10.1182/blood.v106.11.2087.2087.

Full text

Abstract:

Abstract For patients with recurrent and refractory Hodgkin Disease (HD), the major risk after standard treatment with high-dose chemotherapy and autologous hematopoietic stem cell rescue (ASCR) is relapse. In the setting of allogeneic SCT, the graft-vs.-lymphoma effect is offset by high transplant-related mortality. The Children’s Oncology Group has therefore undertaken a study of immunotherapy to induce autologous graft-vs.-host disease (auto GVHD) in an effort to reduce the relapse rate without excessive morbidity and mortality. The objectives of part I of the study were to determine the to

APA, Harvard, Vancouver, ISO, and other styles

13

Ryan, Sean, Derek Abbott, and Brian Cobb. "Targeted modification of complex N-glycosylation results in a spontaneous CVID-like immunodeficiency with anti-lymphocyte autoimmunity (BA14P.204)." Journal of Immunology 192, no. 1_Supplement (2014): 178.5. http://dx.doi.org/10.4049/jimmunol.192.supp.178.5.

Full text

Abstract:

Abstract Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency affecting humans. Although a clear disease etiology remains elusive, a common characteristic of CVID is deficient IgG antibody production to infection or vaccination. Many patients also exhibit symptoms of abnormal T cell function, including an apparent lack of naïve T cells which correlates with clinical severity. We describe here one of the first animal models of spontaneous CVID that incorporates aspects of both humoral and T cell dysfunction. The CVID mice exhibit characteristic defi

APA, Harvard, Vancouver, ISO, and other styles

14

Yang, Chen-lu, Neng-gang Jiang, Li Zhang, Kai Shen, and Yu Wu. "Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation." Therapeutic Advances in Hematology 12 (January 2021): 204062072198957. http://dx.doi.org/10.1177/2040620721989578.

Full text

Abstract:

Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM). MM with plasma-cell leukemia (PCL) transformation is highly aggressive and is resistant to conventional therapy. Novel therapeutics are needed for PCL, and daratumumab may play role. We report a case of relapsed/refractory multiple myeloma (RRMM)-transformed PCL successfully treated with daratumumab. The case was a 42-year-old man who was diagnosed with MM 2 years ago and relapsed after six cycles of bortezomib-based chemotherapy. The patient rapidly developed hyperleukocytosis and diss

APA, Harvard, Vancouver, ISO, and other styles

15

Kadir, Ibrahim Mamadou Abdoul, Amadou Oumarou, and Udou-Daouda Moussa. "Traitement de la maladie de Vogt-Koyanagi-Harada : Une revue narrative de la littérature." Annales Africaines de Medecine 15, no. 1 (2022): e4482-e4491. http://dx.doi.org/10.4314/aamed.v15i1.9.

Full text

Abstract:

Non-traumatic, exudative, bilateral panuveitis associated with extraocular manifestations, Vogt-Koyanagi-Harada disease (VKH) is an autoimmune disease mediated by Th1 lymphocytes reacting against melanocytes. It is a rare disease with female predominance. VKH disease is a diagnostic and therapeutic emergency. Treatment is based mainly on early and aggressive corticosteroid therapy to shorten the duration of the disease, prevent progression to chronicity, and reduce the incidence of extraocular manifestations. It is a corticosteroid-responsive disease, but unfortunately, relapses in the form of

APA, Harvard, Vancouver, ISO, and other styles

16

Koehne, Guenther, Heather Landau, Hani Hassoun, et al. "T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation with Busulfan, Melphalan, and Fludarabine Conditioning Followed by Post Transplantation Donor Lymphocyte Infusions for Patients with Relapsed Multiple Myeloma and High-Risk Cytogenetics." Blood 118, no. 21 (2011): 1992. http://dx.doi.org/10.1182/blood.v118.21.1992.1992.

Full text

Abstract:

Abstract Abstract 1992 Allogeneic hematopoietic stem cell transplantation (allo HSCT) is a curative therapy for patients (pts) with multiple myeloma, but conventional allo HSCT has been associated with unacceptably high rates of mortality. Non-myeloablative allo HSCT has resulted in high rates of acute and chronic graft-versus-host disease (GvHD) and progression. We report results of a pilot study of 13 pts, using T-cell depleted allo HSCT (allo TCD HSCT) from HLA compatible (matched related = 8, matched unrelated = 3, and mismatched unrelated = 2) donors. All 13 pts had relapsed myeloma withi

APA, Harvard, Vancouver, ISO, and other styles

17

Gurina, Olga Petrovna, Elena Aleksandrovna Dementyeva, Aleksandr Evgenevich Blinov, Olga Nikolaevna Varlamova, and Vera Ivanovna Timokhina. "Characteristics of the immune response in children with atopic desoders." Pediatrician (St. Petersburg) 5, no. 4 (2014): 95–103. http://dx.doi.org/10.17816/ped5495-103.

Full text

Abstract:

The study of the immune status of immunopathological reactions and spectral sensitization in children with atopic dermatitis (215 children) and atopic bronchial asthma (197 children) aged 1 month to 17 years. The immune status was investigated by immunological tests of first level, subpopulations of lymphocytes by flow cytome-try, allergodiagnosis, diagnosis of autoimmune antibodies-enzyme-linked immunosorbent assay. Defined heterogeneity of immune system disorders, age-related features of sensitization to the household, food, epidermal and other allergens, the production of IgG autoantibodies

APA, Harvard, Vancouver, ISO, and other styles

18

Montefusco, Vittorio, Francesco Spina, Elena Zamagni, et al. "A Case-Matched Analysis Comparing Lenalidomide After Autologous or After Allogeneic Stem Cell Transplantation Demonstrates a Survival Advantage in Allografted Myeloma Patients." Blood 120, no. 21 (2012): 1960. http://dx.doi.org/10.1182/blood.v120.21.1960.1960.

Full text

Abstract:

Abstract Abstract 1960 Introduction. Lenalidomide (Len) is a highly effective drug against multiple myeloma (MM). It acts through several mechanisms, such as a direct cytotoxic effect, anti-angiogenesis, microenvironment modifications, and immunomodulation. The latter property is particularly interesting in the setting of allogeneic stem cell transplantation (AlloSCT), since Len may interact favourably with the graft-versus-myeloma (GVM) effect. On the other side, the possibility of an over activation of the donor immune system raises some concerns about the safety of this treatment. In order

APA, Harvard, Vancouver, ISO, and other styles

19

Nnadiukwu, C. U., T. A. Nnadiukwu, G. Ajuru, and T. G. Ogono. "Synergistic effect of combined multiple plants extract on some blood cell indices of diabetic rats." Scientia Africana 23, no. 2 (2024): 165–79. http://dx.doi.org/10.4314/sa.v23i2.15.

Full text

Abstract:

This study evaluated the impact of combined therapy of multiple plants extract of Cnestis ferruginea, Xylopia aethiopica, Palisota hirsuta, Scleria sp., Napoleona imperialis, Dialium guineense, Combretum racemosun, Heterotis rotundifolia leaves, stem of Sphenocentrum jollynum stem, and root of Uvaria chamae on blood cell indices of diabetics. Female Wistar rats of 40 – 50 g and fifty-four (54) in number were used for this study. They were assembled into 6 groups of 9 rats each. Group I served as the normal control (NC) while the remaining five groups were induced with diabetes type 2 using hig

APA, Harvard, Vancouver, ISO, and other styles

20

Shune, Leyla, Ayman Qasrawi, Gerhard Hildebrandt, et al. "Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post-Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: A Multicenter Phase II Randomized Clinical Trial." Blood 142, Supplement 1 (2023): 2221. http://dx.doi.org/10.1182/blood-2023-190079.

Full text

Abstract:

Background: By reducing systemic erythropoietin (EPO) levels, in vivo studies showed that hyperbaric oxygen (HBO) promoted homing of transplanted umbilical cord hematopoietic stem/progenitor cells (HSPC) to the bone marrow. In a pilot study, we demonstrated that HBO in autologous HSPC transplantation (auto-HSPC) was well tolerated. Time to absolute neutrophil (ANC) recovery was correlated with HBO-mediated reduction in EPO levels. Methods: In this phase II multicenter clinical trial, patients with multiple myeloma (MM) receiving high-dose melphalan and auto-HSPC were randomized 1:1 between HBO

APA, Harvard, Vancouver, ISO, and other styles

21

Somekh, Ido, Thomas Magg, Alejandro Gallón Duque, et al. "Novel Immune Checkpoint Deficiency and Susceptibility to EBV-Associated Lymphoma." Blood 134, Supplement_1 (2019): 2326. http://dx.doi.org/10.1182/blood-2019-128296.

Full text

Abstract:

Background: Understanding genetic predisposition to cancer is of paramount importance to tailor therapeutic strategies. Several defects in immune checkpoint regulators have been discovered in patients with EBV-induced lymphoma (e.g. CD27, PRKCD, RASGRP1, MAGT1, SH2D1A, ITK). Here, we describe the clinical and immune phenotype of 2 unrelated patients from consanguineous families presenting with a primary immune deficiency (PID) and EBV-associated lymphoproliferation due to biallelic mutations in CD137 (TNFRSF9/4-1BB). Methods: One patient of Turkish origin (P1) and Palestinian origin (P2), resp

APA, Harvard, Vancouver, ISO, and other styles

22

Borthakur, G., S. O’Brien, W. G. Wierda, et al. "Immune anemias in patients with chronic lymphocytic leukemia treated with chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy." Journal of Clinical Oncology 24, no. 18_suppl (2006): 6604. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.6604.

Full text

Abstract:

6604 Background: Auto-immune hemolytic anemia (AIHA) has been reported with the use of fludarabine in the treatment of chronic lymphocytic leukemia (CLL). Since rituximab has been used to treat AIHA, it was anicipated that rituximab might reduce the incidence of AIHA when combined with fludarabine to treat CLL. We analyzed the incidence of immune anemias in 300 patients (pts) with CLL treated with fludarabine, cyclophosphamide and rituximab (FCR) as initial therapy. Methods: Diagnosis of AIHA was based on clinical evidence of hemolysis (elevated indirect bilirubin, reticulocyte count, lactate

APA, Harvard, Vancouver, ISO, and other styles

23

Shi, J., S. Szmania, N. Rosen, et al. "Killer Immunoglobulin-Like Receptor Ligand (KIR-Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM)." Blood 106, no. 11 (2005): 3472. http://dx.doi.org/10.1182/blood.v106.11.3472.3472.

Full text

Abstract:

Abstract Remarkable observations in haplo-identical, T-cell-depleted allogeneic transplantation (Tx) for AML have focused attention on the anti-tumor effects mediated by KIR-lig mismatched NK cells. In this study we evaluated whether haplo-identical KIR-lig-mismatched NK cells transfused after immunosuppression and tumor reduction with high dose chemotherapy and followed by a delayed auto-Tx can improve outcome in high risk MM patients. All 4 patients enrolled had poor prognosis MM (cytogenetically abnormal, high CKS1-B expression) relapsing after tandem (n=3) or single auto-Tx (n=1). The cond

APA, Harvard, Vancouver, ISO, and other styles

24

Carella, Michele, Germana Beltrami, Maria T. Corsetti, et al. "Reduced Intensity Conditioning Regimen for Allografting Following Cytoreductive Autografting in Relapsed/Resistant Hodgkin’s Lymphoma." Blood 104, no. 11 (2004): 5135. http://dx.doi.org/10.1182/blood.v104.11.5135.5135.

Full text

Abstract:

Abstract Background: We postulated that it is possibile to safely extend the benefit of allografting to relapsed or resistant Hodgkin’s Lymphoma (HL) by combining cytoreduction with high-dose therapy/autologous stem cell transplant (HDT/ASCT) and graft versus HL effect mediated through transplanted donor immune cells with nonmyeloablative allografting (RICT). Methods: Twenty-two patients, 32 years of age (range, 16–39) with heavily pretreated disease were given HDT/ASCT. At a median of 92 days after HDT/ASCT the patients received fludarabine 30 mg/m2/day x 3 days and cyclophosphamide 300 mg/m2

APA, Harvard, Vancouver, ISO, and other styles

25

Bharadwaj, Sushma, Eric Lau, Anmol Goyal, et al. "Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)." Blood 142, Supplement 1 (2023): 4878. http://dx.doi.org/10.1182/blood-2023-188166.

Full text

Abstract:

Introduction: Lymphodepletion (LD) is crucial for the expansion and persistence of CAR T cells. Fludarabine in combination with cyclophosphamide (FC) is the LD standard regimen. A national fludarabine shortage in 2022 necessitated the exploration of alternative LD regimens. Bendamustine (benda) is a purine analog and an alkylating chemotherapy that has been used as an LD agent for tisagenlecleucel (Ghilardi et al.,2022). However, there is no data for benda LD in other commonly used CART products for relapsed or refractory non-hodgkin lymphoma (rel/ref NHL). Early safety, efficacy, and expansio

APA, Harvard, Vancouver, ISO, and other styles

26

Lavie, David, John Timmerman, Ramón Garcia Sanz, et al. "KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma." Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS7585. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps7585.

Full text

Abstract:

TPS7585 Background: PD-1 inhibitors are highly effective in patients (pts) with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), but treatment options are limited for pts who have progressed after PD1 blockade. There is an unmet need for effective therapies for anti-PD1 resistant cHL. Upregulation of lymphocyte-activation gene 3 (LAG-3) expression in cHL is proposed to contribute to anti PD-1 resistance (Veldman J et al. Cancer Treat Rev. 2020; 82:101931). The anti–LAG3 antibody favezelimab plus the anti-PD-1 therapy pembrolizumab, has shown promising antitumor activity and manag

APA, Harvard, Vancouver, ISO, and other styles

27

Byrne, Michael T., Yunfeng Dai, Jan Moreb, and Baldeep Wirk. "Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Relapsed After Initial Autologous Hematopoietic Cell Transplantation." Blood 120, no. 21 (2012): 4464. http://dx.doi.org/10.1182/blood.v120.21.4464.4464.

Full text

Abstract:

Abstract Abstract 4464 BACKGROUND: Standard therapy for multiple myeloma (MM) includes initial autologous hematopoietic cell transplantation (autoHCT1) but this is not curative and most patients will relapse. Data on salvage autoHCT2 or allogeneic HCT (alloHCT2) are limited and the optimal salvage strategy is unknown. METHODS: Retrospective review of MM patients over 18 years of age who relapsed after autoHCT1 and underwent salvage autoHCT2 or alloHCT2 between 1995–2011 at our institution. Tandem auto-autoHCT or auto-alloHCT were excluded. Disease response was defined by the International Myel

APA, Harvard, Vancouver, ISO, and other styles

28

Martynova, A., T. Popkova, A. Aleksankin, and E. Gerasimova. "AB0068 B- AND T- LYMPHOCYTE SUBSETS IN PATIENTS WITH EARLY AND PROGRESSED RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1064.2–1065. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3816.

Full text

Abstract:

Background:Role of B- and T- lymphocytes is well established in pathogenesis of rheumatoid arthritis (RA). Self-containing activation of B-cells in ectopic germinative centers is followed by auto-activation of T-lymphocytes while T-cells themselves are antigen-presenting cells for B-lymphocytes [1-2]. As these processes continue with the duration of RA, different subsets of B- and T-cell might be prevalent at different stages of RA.Objectives:Evaluate differences in dynamics of B- and T- cell subsets in early and progressed RA.Methods:53 patients with diagnosed RA(ACR/EULAR 2010 criteria) were

APA, Harvard, Vancouver, ISO, and other styles

29

Siegel, Davi d., Orhan Sezer, Jesus F. San Miguel, et al. "A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma." Blood 112, no. 11 (2008): 2781. http://dx.doi.org/10.1182/blood.v112.11.2781.2781.

Full text

Abstract:

Abstract Panobinostat (LBH589) is a pan-deacetylase inhibitor (pan-DACi), targeting epigenetic and multiple oncogenic pathways. Beyond numerous hematological cell lines being highly sensitive in vitro, panobinostat has shown to induce cytotoxicity at low nanomolar concentrations in multiple myeloma (MM) cell lines resistant to dexamethasone, melphalan, and doxorubicin. Additional in vitro and in vivo experiments have demonstrated potent synergistic MM cytotoxicity of panobinostat and bortezomib associated with blocking of aggresome and proteosome degradation of ubiquinated protein. Collectivel

APA, Harvard, Vancouver, ISO, and other styles

30

Hill, LaQuisa, Oluchi C. Ukaegbu, Bipin N. Savani, et al. "Impact of Different Mobilization Methods on Graft Composition and Outcome after Autologous Stem Cell Transplantation: Implications for Upfront Use of Plerixafor." Blood 124, no. 21 (2014): 1125. http://dx.doi.org/10.1182/blood.v124.21.1125.1125.

Full text

Abstract:

Abstract Early lymphocyte recovery (ELC) is associated with improved outcomes of hematologic malignancies after autologous hematopoietic stem cell transplantation (auto-SCT). ELC, its composition and impact on outcome depends on many variables; however there is limited data on ELC after different mobilization strategies (G-CSF [G] vs. G + high dose cyclophosphamide [GC] vs. G + plerixafor [GP]). Results from a recent study showed that GP based mobilization can affect the number and subsets of immune competent cells contained in the graft. We studied whether these differences are associated wit

APA, Harvard, Vancouver, ISO, and other styles

31

Steinbach, Maya-Leonie C., Jakob Eska, Julia Weitzel, Alexandra R. Görges, Julia K. Tietze, and Manfred Ballmann. "Lung Clearance Index as a Screening Parameter of Pulmonary Impairment in Patients under Immune Checkpoint Therapy: A Pilot Study." Cancers 16, no. 11 (2024): 2088. http://dx.doi.org/10.3390/cancers16112088.

Full text

Abstract:

Background: Immune checkpoint blockade (ICB) has presented a breakthrough in the treatment of malignant tumors and increased the overall survival of patients with various tumor entities. ICB may also cause immune-related adverse events, such as pneumonitis or interstitial lung disease. The lung clearance index (LCI) is a multiple-breath washout technique offering information on lung pathology in addition to conventional spirometry. It measures the degree of pulmonary ventilation inhomogeneity and allows early detection of pulmonary damage, especially that to peripheral airways. Methods: This c

APA, Harvard, Vancouver, ISO, and other styles

32

Shune, Leyla O., Ayman Qasrawi, Gerhard C. Hildebrandt, et al. "Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial." Blood 144, Supplement 1 (2024): 4741. https://doi.org/10.1182/blood-2024-211184.

Full text

Abstract:

Background: In vivo studies showed that hyperbaric oxygen (HBO) promoted the homing of transplanted umbilical cord hematopoietic stem/progenitor cells (HSPC) to the bone marrow by reducing systemic erythropoietin (EPO) levels. In a pilot study, we demonstrated that HBO was well tolerated in autologous HSPC transplantation (auto-HSPC). Time to absolute neutrophil (ANC) recovery was correlated with HBO-mediated reduction in EPO levels. Methods: In this phase II multicenter clinical trial, patients with multiple myeloma (MM) receiving high-dose melphalan and auto-HSPC were randomized 1:1 between

APA, Harvard, Vancouver, ISO, and other styles

33

Kröger, Nicolaus, Tatjana Zabelina, Marion Heinzelmann, et al. "Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma." Blood 114, no. 22 (2009): 1201. http://dx.doi.org/10.1182/blood.v114.22.1201.1201.

Full text

Abstract:

Abstract Abstract 1201 Poster Board I-223 Introduction: Autologous stem cell transplantation followed by a dose-reduced conditioning and allogeneic stem cell transplantation from HLA-identical siblings has become a treatment option for patients with multiple myeloma. However, only a minority of the patients with multiple myeloma has an HLA-identical sibling and the experience using unrelated donor in this setting is limited. Patients and Methods: From 1997 to 2007, 73 patients (male:45; female:28) with multiple myeloma stage II/III and a median age of 49 years (r, 29-64) were included in a pro

APA, Harvard, Vancouver, ISO, and other styles

34

Mohamed, Amany Ihab, Simon Bulley, Julie Tarrant, et al. "Opsoclonus-Myoclonus Syndrome and Acquired Von Willebrand Syndrome As Manifestations of Graft-Versus-Host Disease." Blood 142, Supplement 1 (2023): 7034. http://dx.doi.org/10.1182/blood-2023-187798.

Full text

Abstract:

Background: Opsoclonus-myoclonus syndrome (OMS), known as dancing eye syndrome, is a rare neurological disorder characterised by a triad of opsoclonus (rapid, involuntary eye movements), myoclonus (uncontrolled muscle twitches) and ataxia. The syndrome is usually seen in children, often associated with neuroblastoma, and is extremely rare in adults. The pathogenesis is thought to be immune in nature and aetiology is variable although most cases are associated with solid tumors or after an infection. Treatment involves a combination of managing the underlying condition and immunosuppression. Ac

APA, Harvard, Vancouver, ISO, and other styles

35

Iovino, Lorenzo, Enrico Orciuolo, Gabriele Buda та ін. "Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ NaϊVe and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study". Blood 128, № 22 (2016): 1230. http://dx.doi.org/10.1182/blood.v128.22.1230.1230.

Full text

Abstract:

Abstract Introduction: Immune reconstitution after stem cell transplantation (SCT) plays a crucial role in host defense against microbial agents. The thymus atrophy occurring with ageing represents a limit for de novo T-cell reconstitution, although the reactivation of thymic function after BMT is documented. The proper strategy to improve the thymic output is currently matter of debate. Pre-clinical and clinical evidences suggest that Zinc oral supplementation may contribute to thymic reactivation and to improve the T-mediated cellular defense against pathogens. We tested the role of Zinc ora

APA, Harvard, Vancouver, ISO, and other styles

36

Giaccone, Luisa, Andrea Evangelista, Francesca Patriarca, et al. "Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs." Blood 128, no. 22 (2016): 3469. http://dx.doi.org/10.1182/blood.v128.22.3469.3469.

Full text

Abstract:

Abstract Introduction: Before the introduction of new drugs, we designed a trial where treatment of newly diagnosed multiple myeloma (MM) patients with double autografts or autograft followed by nonmyeloablative allograft was based on the presence or absence of HLA identical siblings (Bruno B et al. N Engl J Med 2007) We reported an update with special focus on long term outcomes. Methods: From September 1998 to July 2004, 162 consecutive patients with newly diagnosed MM up to the age of 65 years and at least one sibling were enrolled at 5 Italian centers, and divided into 2 groups: donor (N=8

APA, Harvard, Vancouver, ISO, and other styles

37

Koehne, Guenther, Sean M. Devlin, Heather Landau, et al. "T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation For Patients With Relapsed Multiple Myeloma and High-Risk Cytogenetics Permits Long-Lasting Remissions In The Absence Of Graft-Versus-Host Disease." Blood 122, no. 21 (2013): 2115. http://dx.doi.org/10.1182/blood.v122.21.2115.2115.

Full text

Abstract:

Abstract Introduction Pts with high-risk cytogenetics and/or relapsed multiple myeloma (MM) post autologous transplant have a particularly limited prognosis. Conventional allogeneic hematopoietic stem cell transplantation (allo HSCT) has been associated with unacceptably high rates of mortality and non-myeloablative allo HSCT has resulted in high rates of acute and chronic graft-versus-host disease (GvHD) and progression. Methods We report results of a phase II clinical trial of 34 pts, using T-cell depleted allo HSCT (allo TCD HSCT) from HLA compatible (matched related = 12, matched unrelated

APA, Harvard, Vancouver, ISO, and other styles

38

Prata, Karen L., Gil C. De Santis, Maria Carolina B. Oliveira, et al. "Mobilization, Collection, Infusion and Granulocyte Recovery of PBSC in Type 1 Diabets Mellitus Pacients after High Dose Immunosupression." Blood 108, no. 11 (2006): 5224. http://dx.doi.org/10.1182/blood.v108.11.5224.5224.

Full text

Abstract:

Abstract Background. Type 1 diabetes mellitus (T1DM) is an autoimmune disease. A safe induction of an autoimmunity-free status may become a promising therapy. We hypothesize that intense immuno- and myelosuppression followed by autologous hematopoietic stem cell (HSC) rescue is an option to establish a lasting immunetolerance by eliminating auto-reactive lymphocytes and thus facilitate a possible recovery of autologous insulin production. Aims. Evaluate the HSC mobilization, infusion and engraftment in T1DM patients. Patients and Methods. Between January of 2004 and July of 2006 15 T1DM patien

APA, Harvard, Vancouver, ISO, and other styles

39

Foieni, Fabrizio, Andrea Zanichelli, Anna Coerezza, et al. "Lymphoproliferative Disorder and Acquired C1-INH Deficiency. A Case Series of 48 Patients." Blood 118, no. 21 (2011): 1596. http://dx.doi.org/10.1182/blood.v118.21.1596.1596.

Full text

Abstract:

Abstract Abstract 1596 Angioedema with acquired deficiency of C1 inhibitor (C1-INH) is a rare syndrome associated with B lymphocyte disorders, usually identified as acquired angioedema (AAE). The clinical features of C1-INH deficiency, more often of genetic origin (hereditary angioedema HAE), include subcutaneous swelling, edema of the gastrointestinal wall causing temporary bowel obstruction with severe pain and edema of the upper respiratory tract that can lead to asphyxia. AAE associated B cell disorders result in autoantibodies to C1-INH, monoclonal gammopathies of uncertain significance (

APA, Harvard, Vancouver, ISO, and other styles

40

Hong, Yaqun, Xiaofan Li, Xianling Chen, et al. "Combination of Four Drugs for Bloodstream Infection Caused By Carbapenem-Resistant Enterobacteriaceae in Severe Agranulocytosis Patients after Hematopoietic Stem Cell Transplantation." Blood 134, Supplement_1 (2019): 5664. http://dx.doi.org/10.1182/blood-2019-128257.

Full text

Abstract:

Bloodstream infection (BSI) caused by multidrug‐resistant bacteria (MDRB) or extensively drug-resistant bacteria (XDRB) in immunocompromised and neutropenic patients after hematopoietic stem cell transplantation (HSCT) is a global threaten. However, effective treatment regimen is still controversial and inadequate due to the rapid deterioration, the horrific evolution of bacteria and high mortality that the mortality related to BSI caused by carbapenem-resistant Enterobacteriaceae (CRE) is 51% in adult neutropenic patients[1]. Here, we presented four cases that CRE was detected in blood of sev

APA, Harvard, Vancouver, ISO, and other styles

41

Hirbod-Mobarakeh, Armin, Hesam Addin Gordan, Zahra Zahiri, et al. "Specific immunotherapy in renal cancer: a systematic review." Therapeutic Advances in Urology 9, no. 2 (2016): 45–58. http://dx.doi.org/10.1177/1756287216681246.

Full text

Abstract:

Background: Renal cell cancer (RCC) is the tenth most common malignancy in adults. In recent years, several approaches of active and passive immunotherapy have been studied extensively in clinical trials of patients with RCC. The aim of this systematic review was to assess the clinical efficacy of various approaches of specific immunotherapy in patients with RCC. Methods: We searched Medline, Scopus, CENTRAL, TRIP, DART, OpenGrey and ProQuest without any language filter through to 9 October 2015. One author reviewed search results for irrelevant and duplicate studies and two other authors inde

APA, Harvard, Vancouver, ISO, and other styles

42

Peltier, Dan, Nicolas Robine, Guoqing Hou, and Pavan Reddy. "RNA-Seq of Human T Cells after BMT Identifies Linc00402 As a Novel Regulator of Human T Cell Alloimmunity." Blood 132, Supplement 1 (2018): 4517. http://dx.doi.org/10.1182/blood-2018-99-113017.

Full text

Abstract:

Abstract The mechanisms governing human allogeneic T cell responses remain incompletely understood which limits the wider clinical application of allo-BMT. Long non-coding RNAs (lncRNA) are an emerging class of non-coding RNAs that control gene expression with tissue and context specificity. However, their role in alloimmunity is unknown. To determine whether lncRNAs regulate T cell alloimmunity we performed RNA-seq of donor T cells following clinical BMT to identify and characterize differentially-expressed lncRNAs. CD3+ T cells 30 days post myeloablative BMT were isolated in a discovery coho

APA, Harvard, Vancouver, ISO, and other styles

43

Apostolidis, John, Nihad Mokhtar, Mohammed Darweesh, et al. "Excellent Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Eastern Province of Saudi Arabia. a Real-World Case Series of 49 Consecutive Patients Treated at a Referral Center from 2006 to 2017." Blood 132, Supplement 1 (2018): 5365. http://dx.doi.org/10.1182/blood-2018-99-113279.

Full text

Abstract:

Abstract Background Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare subtype of HL for which optimal treatment is controversial. We retrospectively reviewed the files of patients with NLPHL diagnosed and followed up at our institution and describe clinical characteristics and outcome and explore prognostic factors for progression-free survival (PFS) and overall survival (OS). Methods We included consecutive patients diagnosed with NLPHL and followed at King Fahad Specialist Hospital, Damamm (KFSH-D), a referral center for the Eastern Province of Saudi Arabia. Primary aim of th

APA, Harvard, Vancouver, ISO, and other styles

44

Lane, H. C., and A. S. Fauci. "Immunologic Approaches to the Therapy of Auto-Immune Salivary Gland Disease." Journal of Dental Research 66, no. 1_suppl (1987): 703–8. http://dx.doi.org/10.1177/00220345870660s117.

Full text

Abstract:

A variety of immunologic mechanisms may theoretically give rise to disease in the salivary glands. Among them are abnormal antibody production, hyper-reactive T-lymphocytes, and mono- or oligoclonal expansions of B-lymphocytes, While it is not clear which, if any, of these mechanisms are of prime importance in the immunopathology of salivary gland disease, they provide a framework, within which to discuss theoretical approaches to the treatment of auto-immune salivary gland disease. Among the techniques used to decrease antibody-induced damage are non-steroidal anti-inflammatory agents, plasma

APA, Harvard, Vancouver, ISO, and other styles

45

Karp, Judith E., B. Douglas Smith, Jacqueline Greer, et al. "Phase II Clinical Trial of Flavopiridol (FL) Followed by ara-c and Mitoxantrone (AM) for Adults with Relapsed and Refractory Acute Leukemias." Blood 106, no. 11 (2005): 2784. http://dx.doi.org/10.1182/blood.v106.11.2784.2784.

Full text

Abstract:

Abstract The cell cycle inhibitor FL targets cyclin-dependent kinases, induces checkpoint arrest and interrupts transcriptional elongation. We demonstrated in an in vitro model that F causes apoptosis in leukemic blasts and increases A cytotoxicity in remaining blasts (Clin Cancer Res9: 307–315, 2003). Based on these observations, we have conducted a Phase II trial of timed sequential therapy (TST) with FL 50 mg/m2 daily x 3 days followed by A 2 gm/m2/72 hr infusion beginning day 6 and M 40 mg/m2 day 9 (FLAM). A total of 42 adults (median age 50, range 23–75) received FLAM for acute myelogenou

APA, Harvard, Vancouver, ISO, and other styles

46

Neelapu, Sattva S., Rajneesh Nath, Javier Munoz, et al. "ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T." Blood 138, Supplement 1 (2021): 3878. http://dx.doi.org/10.1182/blood-2021-146038.

Full text

Abstract:

Abstract Background Allogeneic (off the shelf) chimeric antigen receptor (CAR) T-cell therapy addresses the logistical challenges, availability (including insufficient T-cell yields from low baseline absolute lymphocyte count), and variable product quality of autologous CAR T therapy. ALLO-501 is a genetically modified anti-CD19 AlloCAR T™ cell product that uses TALEN ® gene editing to disrupt the T-cell receptor alpha constant gene and the CD52 gene with TALEN to reduce the risk of graft-versus-host disease (GvHD) and permit the use of ALLO-647 (anti-CD52 monoclonal antibody [mAb]), for selec

APA, Harvard, Vancouver, ISO, and other styles

47

Ansell, Stephen, Martin E. Gutierrez, Margaret A. Shipp, et al. "A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)." Blood 128, no. 22 (2016): 183. http://dx.doi.org/10.1182/blood.v128.22.183.183.

Full text

Abstract:

Abstract Introduction: Nivolumab (nivo) is a fully human IgG4 monoclonal antibody (mAb) targeting programmed death receptor-1 (PD-1). Nivo has demonstrated clinical activity and an acceptable safety profile in a phase 1b study (NCT01592370; CheckMate 039) in patients (pts) with relapsed/refractory hematologic malignancies. In pts diagnosed with Hodgkin lymphoma (HL), after a median 86 weeks of follow-up, 7/20 responders maintained a response for >1.5 years (Ansell S et al. Blood 2015;126:583), and after a median follow-up of 67 weeks, clinical activity (investigator-assessed objective respo

APA, Harvard, Vancouver, ISO, and other styles

48

Goekbuget, Nicola, Renate Arnold, Johannes Atta, et al. "Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT)." Blood 106, no. 11 (2005): 150. http://dx.doi.org/10.1182/blood.v106.11.150.150.

Full text

Abstract:

Abstract In the recent years T-ALL/LBL has turned to a favourable subtype of adult ALL due to intensive chemotherapy and/or SCT in first CR. At relapse, however, the disease is highly refractory and rapidly progressive. In the GMALL study 05/93 in ‘early’ relapse during therapy the CR rate with HD regimens was 29% and the survival 8%. The major problem was achievement of CR in order to proceed to SCT. Therefore the T-cell specific purine analogue compound GW506U78 (NSC 686673, Nelarabine) was evaluated. The compound was provided by the National Cancer Institute and administered as single drug

APA, Harvard, Vancouver, ISO, and other styles

49

Palmisani, Elena, Gianluca Dell'Orso, Erica Del Bò, et al. "Early Detection of Immune-Dysregulation Predicts a Better Response to Immunosuppressive Treatment in Chronic Immune Thrombocytopenia." Blood 144, Supplement 1 (2024): 5397. https://doi.org/10.1182/blood-2024-207549.

Full text

Abstract:

Introduction: chronicimmune thrombocytopenia (ITP) is a highly heterogeneous condition in terms of clinical course and response to treatment and it could represent the epiphenomenon of a complex immune-dysregulation process. Not all patients respond with equal effectiveness to different therapeutic approaches. However, specific indicators to predict therapeuthic response to the most suitable second-line therapy (mycophenolate mofetile, sirolimus and TPO agonists) in the acute phase have not yet been identified. Aims: to describe the clinical and immunological features and the treatment respons

APA, Harvard, Vancouver, ISO, and other styles

50

Tawara, Isao, Masahiro Masuya, Shinichi Kageyama, et al. "Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia." Blood 126, no. 23 (2015): 97. http://dx.doi.org/10.1182/blood.v126.23.97.97.

Full text

Abstract:

Abstract Wilms' Tumor 1 (WT1) is expressed in a majority of MDS and AML cells and mRNA of WT1 in peripheral blood and bone marrow is monitored as a marker of minimal residual disease of AML and MDS. Several WT1 protein-derived epitopes that are recognized by cytotoxic T lymphocytes (CTLs) along with HLA molecules are determined. In vitro study and WT1 peptide vaccine trials have demonstrated that WT1-specfic CD8+ T cells with cytotoxic activity can be induced. Adoptive T cell therapy using ex vivo expanded WT1-specific CTLs or WT1-specific T-cell receptor (TCR)-gene transduced cells are potent

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!